BioCryst to Report Third Quarter 2025 Financial Results on November 3
BioCryst (Nasdaq: BCRX) will report third quarter 2025 financial results on Monday, November 3, 2025. Management will host a conference call and live webcast at 8:30 a.m. ET to discuss results and provide a corporate update.
Dial-in numbers are 1-844-481-2942 (U.S.) and 1-412-317-1866 (international). A live webcast and replay will be available in the investors section of the company website at www.biocryst.com.
BioCryst (Nasdaq: BCRX) riferirà i risultati finanziari del terzo trimestre 2025 il lunedì 3 novembre 2025. Il management ospiterà una conference call e una webcast in diretta alle 8:30 a.m. ET per discutere i risultati e fornire un aggiornamento aziendale.
I numeri di accesso sono 1-844-481-2942 (USA) e 1-412-317-1866 (internazionale). Una webcast in diretta e una replica saranno disponibili nella sezione investitori del sito web dell'azienda all'indirizzo www.biocryst.com.
BioCryst (Nasdaq: BCRX) reportará los resultados financieros del tercer trimestre de 2025 el lunes 3 de noviembre de 2025. La dirección organizará una llamada de conferencia y una transmisión web en vivo a las 8:30 a.m. ET para discutir los resultados y proporcionar una actualización corporativa.
Los números de marcación son 1-844-481-2942 (EE. UU.) y 1-412-317-1866 (internacional). Una transmisión web en vivo y una reproducción estarán disponibles en la sección de inversores del sitio web de la empresa en www.biocryst.com.
BioCryst (나스닥: BCRX)는 2025년 3분기 재무 실적을 2025년 11월 3일 월요일에 발표합니다. 경영진은 동부 표준시 8:30에 컨퍼런스 콜과 라이브 웹캐스트를 주최하여 실적을 논의하고 회사 업데이트를 제공합니다.
다이얼 번호는 1-844-481-2942 (미국) 및 1-412-317-1866 (해외)입니다. 라이브 웹캐스트와 리플레이는 회사 웹사이트의 투자자 섹션에서 www.biocryst.com으로 제공됩니다.
BioCryst (NASDAQ : BCRX) publiera les résultats financiers du troisième trimestre 2025 le lundi 3 novembre 2025. La direction organisera une conférence téléphonique et une webdiffusion en direct à 8h30, heure de l'Est pour discuter des résultats et fournir une mise à jour de l'entreprise.
Les numéros à composer sont 1-844-481-2942 (États-Unis) et 1-412-317-1866 (international). Une webdiffusion en direct et une reprise seront disponibles dans la section investisseurs du site web de l'entreprise à l'adresse www.biocryst.com.
BioCryst (Nasdaq: BCRX) wird die Finanzergebnisse des dritten Quartals 2025 am Montag, dem 3. November 2025 bekanntgeben. Das Management wird einen Conference Call und einen Live-Webcast um 8:30 Uhr ET abhalten, um Ergebnisse zu besprechen und ein Unternehmensupdate bereitzustellen.
Wählnummern sind 1-844-481-2942 (USA) und 1-412-317-1866 (international). Ein Live-Webcast und eine Aufzeichnung werden im Bereich Investorenseite der Unternehmenswebsite unter www.biocryst.com verfügbar sein.
BioCryst (ناسداك: BCRX) سيُعلن عن نتائج الربع الثالث من 2025 في الإثنين 3 نوفمبر 2025. سيعقد الإدارة مؤتمراً هاتفياً وبثاً حيّاً عبر الويب في الساعة 8:30 صباحاً بتوقيت شرق الولايات المتحدة لمناقشة النتائج وتوفير تحديث للشركة.
أرقام الاتصال هي 1-844-481-2942 (الولايات المتحدة) و 1-412-317-1866 (دولي). سيكون هناك بث حي عبر الويب وإعادة عرض متاحة في قسم المستثمرين من موقع الشركة على الويب www.biocryst.com.
BioCryst (纳斯达克：BCRX) 将于 2025 年第三季度 财务业绩于 2025 年 11 月 3 日，星期一 公布。管理层将主持电话会议和现场网络直播，时间为 美东时间 8:30，以讨论业绩并提供公司更新。
拨号号码为 1-844-481-2942（美国）和 1-412-317-1866（国际）。现场网络直播及回放将可在公司网站投资者板块的 www.biocryst.com 获取。
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2025 financial results on Monday, November 3, 2025.
BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
Investors:
investorrelations@biocryst.com
Media:
media@biocryst.com
FAQ
When will BioCryst (BCRX) report third quarter 2025 results?
What time is the BioCryst (BCRX) Q3 2025 conference call and webcast?
How can investors join the BioCryst (BCRX) earnings call on November 3, 2025?
Where can I watch the BioCryst (BCRX) webcast and access the replay for Q3 2025?
Will BioCryst (BCRX) provide a corporate update during the Q3 2025 call?
